Abstract: Nanostructures formed from a plurality of structural units in which the positions of the structural units relative to each other are established in a defined geometry, are formed by sequentially adding structural units to a growing structure to build up the nanostructure. The nanostructure includes two or more species of protein structural units, and each structural unit is added to the growing structure in a separate structural unit-addition step. Structural units not incorporated in the growing structure is removed at the end of each structural unit-addition step. Each species of structural unit has the ability to assemble non-covalently with the growing nanostructure to which it is added but cannot self-assemble with other structural units of the same species.

Abstract: Nanostructures are made that include at least one species of assembly unit that is an antibody assembly unit in which at least one joining element, structural element or functional element is an antibody or antibody fragment. Antibody assembly units may have more than one antibody element. In addition, the antibody assembly units may contain non-antibody structural, functional or joining elements. The nanostructure is suitably prepared using a staged assembly method. In this method, a nanostructure intermediate having at least one unbound joining element is contacted with an assembly unit having a plurality of different joining elements. None of the joining elements of the assembly unit can interact with itself or with another joining element of the same assembly unit.

Abstract: The present invention pertains to nanostructures, i.e., nanometer sized structures useful in the construction of microscopic and macroscopic structures. In particular, the present invention pertains to nanostructures based on bacteriophage T4 tail fiber proteins and variants thereof.

Abstract: Nanostructures are made that include at least one species of assembly unit comprising a peptide nucleic acid (PNA). PNA assembly units may have one or two PNA joining elements. In addition, the PNA assembly units may contain structural elements, and/or other functional or joining elements. The nanostructure is suitably prepared using a staged assembly method. In this method, a nanostructure intermediate having at least one unbound joining element is contacted with an assembly unit having a plurality of different joining elements. None of the joining elements of the assembly unit can interact with itself or with another joining element of the same assembly unit. However, one of the joining elements of the assembly unit can interact with the unbound joining element of the nanostructure intermediate, so that the assembly unit is non-covalently bound to the nanostructure intermediate to form a new nanostructure intermediate for use in subsequent cycles.

Abstract: The present invention pertains to nanostructures, i.e., nanometer sized structures useful in the construction of microscopic and macroscopic structures. In particular, the present invention pertains to nanostructures based on bacteriophage T4 tail fiber proteins and variants thereof.

Abstract: The present invention pertains to nanostructures. i.e. nanometer sized structures useful in the construction of microscopic and macroscopic structures. In particular, the present invention pertains to nanostructures based on bacteriophage T4 tail fiber proteins and variants thereof. More specifically, the present invention relates to polypeptides comprising modified gp37 tail fiber proteins of bacteriophage T4.

Abstract: The present invention pertains to nanostructures, i.e., nanometer sized structures useful in the construction of microscopic and macroscopic structures. In particular, the present invention pertains to nanostructures based on bacteriophage T4 tail fiber proteins and variants thereof.

Abstract: Compositions comprising lanthionine-containing bacteriocins such as nisin in combination with a chelator act as bactericides in low pH environments. In a preferred embodiment pharmaceutical preparations containing the compositions are used for the control of bacteria responsible for disorders of the gastrointestinal tract.

Abstract: Compositions comprising lanthionine-containing bacteriocins such as nisin act as bactericides under conditions such as those found in the gastrointestinal tract. In a preferred embodiment pharmaceutical preparations containing the compositions are used for the control of bacteria responsible for disorders of the gastrointestinal tract.

Abstract: An improved assay for measuring the quantity of Beta-lactam antibiotics, particularly valuable for measuring penicillin in milk. The assay includes the covalent-attachment of a penicillin to a penicillin-binding-protein bound to a matrix, the highly selective attachment of an antibody to such a conjugate, and the detection and measurement of the quantity of resulting antibody-complex material as a direct measure of the amount of penicillin in the milk being tested.